{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:22:53Z","timestamp":1791292973773,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.cjca.2014.10.022","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T01:18:02Z","timestamp":1419038282000},"page":"3-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications"],"prefix":"10.1016","volume":"31","author":[{"given":"Gordon W.","family":"Moe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O'Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-9740","authenticated-orcid":false,"given":"Serge","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Fremes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Al-Hesayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrellita","family":"Estrella-Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Grzeslo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Harkness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri L.","family":"Koshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McKelvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Swiggum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Malcolm O.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"D'Astous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabe","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haissam","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Sussex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.10.022_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0828-282X(06)70237-9","article-title":"Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management","volume":"22","author":"Arnold","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0828-282X(07)70211-8","article-title":"Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers","volume":"23","author":"Arnold","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0828-282X(09)70477-5","article-title":"Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy, and recent important clinical trials","volume":"25","author":"Howlett","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0828-282X(10)70367-6","article-title":"The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement\/assurance programs","volume":"26","author":"Howlett","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0828-282X(08)70545-2","article-title":"Canadian Cardiovascular Society Consensus Conference guidelines on heart failure\u20132008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies","volume":"24","author":"Malcom","year":"2008","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cjca.2011.03.011","article-title":"The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care","volume":"27","author":"McKelvie","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cjca.2013.10.010","article-title":"The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization","volume":"30","author":"Moe","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib9","first-page":"1326","article-title":"Adding \u201cvalue\u201d to clinical practice guidelines","volume":"53","author":"McCormack","year":"2007","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.cjca.2014.10.022_bib10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0735-1097(03)00425-X","article-title":"Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE)","volume":"41","author":"Mozaffarian","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib11","series-title":"Vitamin and Mineral Nutrition Information System (VMNIS). Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.cjca.2014.10.022_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2004.08.039","article-title":"Prevalence of anemia and effects on mortality in patients with heart failure","volume":"149","author":"Lindenfeld","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.hfc.2010.03.007","article-title":"Epidemiology of anemia in heart failure","volume":"6","author":"Tang","year":"2010","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cjca.2014.10.022_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.105.583666","article-title":"Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options","volume":"113","author":"Tang","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.CIR.0000052623.16194.80","article-title":"Hemodilution is common in patients with advanced heart failure","volume":"107","author":"Androne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jacc.2007.07.094","article-title":"Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure","volume":"51","author":"Tang","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/eurheartj\/ehi388","article-title":"Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure","volume":"26","author":"Opasich","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3892\/etm.2013.1307","article-title":"Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia","volume":"6","author":"Guo","year":"2013","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCHEARTFAILURE.114.001100","article-title":"Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes","volume":"7","author":"O\u2019Meara","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2014.10.022_bib25","first-page":"43","article-title":"Impact of oral iron therapy on quality of life in patients with heart failure","volume":"2","author":"Manjunath","year":"2014","journal-title":"Int J Basic Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.10.022_bib26","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib27","doi-asserted-by":"crossref","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et\u00a0al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2014; doi:10.1093\/eurheartj\/ehu385.","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"10.1016\/j.cjca.2014.10.022_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurjhf\/hfs017","article-title":"Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis","volume":"14","author":"Avni","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","article-title":"Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia","volume":"117","author":"Ghali","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib30","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.hfc.2013.11.002","article-title":"Anemia and iron deficiency in heart failure","volume":"10","author":"Arora","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cjca.2014.10.022_bib32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jchf.2014.02.005","article-title":"Charting a roadmap for heart failure biomarker studies","volume":"2","author":"Ahamad","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib33","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.110.979500","article-title":"Natriuretic peptide testing in heart failure","volume":"123","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib34","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0735-1097(03)00405-4","article-title":"Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study","volume":"41","author":"Maisel","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5 suppl","key":"10.1016\/j.cjca.2014.10.022_bib35","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cardfail.2005.04.011","article-title":"The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study","volume":"11","author":"O\u2019Donoghue","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ehj.2004.03.004","article-title":"Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC\/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes","volume":"25","author":"Bazzino","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.105.552216","article-title":"N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism","volume":"112","author":"Binder","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1183\/09031936.00095606","article-title":"NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension","volume":"29","author":"Blyth","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.10.022_bib40","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1161\/01.CIR.0000060533.79248.0C","article-title":"Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis","volume":"107","author":"Gerber","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacc.2004.10.057","article-title":"Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy","volume":"45","author":"Lindahl","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ahj.2006.10.005","article-title":"Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study","volume":"153","author":"Morello","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib43","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib44","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","volume":"54","author":"Cleland","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archinte.166.3.315","article-title":"Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department","volume":"166","author":"Januzzi","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-153-11-201012070-00006","article-title":"Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting","volume":"153","author":"Lam","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib47","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/CIRCULATIONAHA.106.666255","article-title":"N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study","volume":"115","author":"Moe","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib48","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archinte.166.10.1081","article-title":"Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea","volume":"166","author":"Mueller","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib49","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.cjca.2014.04.012","article-title":"Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3)","volume":"30","author":"Ezekowitz","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/heartjnl-2012-302313","article-title":"Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"99","author":"Thomas","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2014.10.022_bib51","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib52","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","volume":"56","author":"Eurlings","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib53","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib54","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.10.081","article-title":"Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study","volume":"49","author":"Jourdain","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib56","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","article-title":"Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure\u2013SIGNAL-HF (Swedish Intervention study\u2013Guidelines and NT-proBNP AnaLysis in Heart Failure)","volume":"12","author":"Persson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.10.022_bib58","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","article-title":"The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure","volume":"17","author":"Shah","year":"2011","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.10.022_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib61","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ahj.2009.06.018","article-title":"Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"158","author":"Felker","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinternmed.2010.35","article-title":"B-type natriuretic peptide-guided heart failure therapy: a meta-analysis","volume":"170","author":"Porapakkham","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib64","first-page":"4","article-title":"The integration of BNP and NT-proBNP into clinical medicine","volume":"137","author":"Mueller","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.cjca.2014.10.022_bib65","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2003.09.044","article-title":"Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure","volume":"43","author":"Logeart","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2013-303632","article-title":"A\u00a0novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score","volume":"100","author":"Salah","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2014.10.022_bib67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.10.022_bib68","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib69","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.108.807271","article-title":"Association of cystatin C with left ventricular structure and function: the Dallas Heart Study","volume":"2","author":"Patel","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCHEARTFAILURE.113.000242","article-title":"Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure","volume":"7","author":"van Deursen","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib72","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","article-title":"Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure","volume":"116","author":"Latini","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib73","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCHEARTFAILURE.113.000450","article-title":"Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial","volume":"7","author":"Gravning","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/CIRCULATIONAHA.111.044149","article-title":"Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials","volume":"125","author":"Masson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib75","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjhf\/hfr047","article-title":"Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure","volume":"13","author":"Pascual-Figal","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib76","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/bmm.09.56","article-title":"ST2 protein in heart disease: from discovery to mechanisms and prognostic value","volume":"3","author":"Weinberg","year":"2009","journal-title":"Biomark Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib78","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12265-013-9459-y","article-title":"ST2 as a cardiovascular risk biomarker: from the bench to the bedside","volume":"6","author":"Januzzi","year":"2013","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.cjca.2014.10.022_bib79","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.jacc.2008.09.027","article-title":"Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load","volume":"52","author":"Bartunek","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib80","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib81","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","article-title":"Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results","volume":"165","author":"Wu","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.10.022_bib82","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cardfail.2013.09.005","article-title":"Soluble ST2 serum concentration and renal function in heart failure","volume":"19","author":"Bayes-Genis","year":"2013","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.10.022_bib83","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib85","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.10.022_bib86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.10.022_bib87","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","article-title":"Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition","volume":"44","author":"Cruden","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.10.022_bib88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000092457","article-title":"Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase","volume":"103","author":"Maric","year":"2006","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.cjca.2014.10.022_bib89","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005344-199801000-00017","article-title":"Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II","volume":"31","author":"Rademaker","year":"1998","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2014.10.022_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.10.022_bib91","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.10.022_bib92","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.cjca.2015.06.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000}}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14014925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14014925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T12:59:35Z","timestamp":1566133175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14014925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0828282X14014925"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.10.022","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.cjca.2015.06.014","asserted-by":"object"}]},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2014.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}